Carl Gordon

Carl Gordon

Vermogen: 52 868 $ op 31-07-2026

61 jaar
Health Technology
Finance
Technology Services

Profiel

Carl Lee Gordon is the founder of OrbiMed Advisors LLC, founded in 1989, serving as Managing Partner since 2018.
Current jobs include Chairman at Compass Therapeutics, Inc. since 2019; Director at Sapphire Therapeutics, Inc., Amnis Corp.
since 2008, Singulex, Inc. since 2007, Adimab LLC, Agensys, Inc., X4 Pharmaceuticals (Austria) GmbH, Gemini Therapeutics Sub, Inc., Emendo Biotherapeutics, Inc., Kumquat Biosciences, Inc., Frontera Therapeutics (HK) Ltd., XinThera, Inc., Gwynant Therapeutics, Inc., Stratus Therapeutics, Inc., Electra Therapeutics, Inc., Star OpCo, Inc., Avenzo Therapeutics, Inc. as Independent Director, The New York City Investment Fund Manager, Inc. as Advisor, and Aragon Pharmaceuticals, Inc. as Principal.
Director roles also include Lomond Therapeutics Holdings, Inc. since 2024, Scribe Therapeutics, Inc. and Blossomhill Therapeutics, Inc. since 2021, OrbiMed Advisors Private Equity since 1995 as Managing Partner, and others.
Former jobs include Independent Director at MBX Biosciences, Inc. (2020–2025), Arrivent BioPharma, Inc. (2022–2025), Selecta Biosciences, Inc. (2010–2017), Arsanis, Inc. (2010–2019), Alector, Inc. (2013–2019), Oric Pharmaceuticals, Inc. (2015–2021), and others.
Director roles were held at BioCryst Pharmaceuticals, Inc. (2004–2007),.
Amarin Corp.
Plc (2012–2013), Arius Research, Inc. (2006–2009), Acceleron Pharma, Inc. (2006–2013), Complete Genomics, Inc. (2011–2012), Pacira Biosciences, Inc. (2011), Theseus Pharmaceuticals, Inc. (2018–2024), Kinnate Biopharma, Inc. (2019–2024), Gemini Therapeutics, Inc. (2016–2022), Prevail Therapeutics, Inc. (2017–2021), Terns Pharmaceuticals, Inc. (2018–2025), Passage Bio, Inc. (2018–2020), and others.
Education includes a doctorate from Massachusetts Institute of Technology conferred in 1993 and an undergraduate degree from Harvard College conferred in 1987.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
04-06-2025 5.250 ( 0,03% ) 52 868 $ 31-07-2026
31-03-2026 0 ( -.--% ) - $ 31-07-2026
06-08-2026 0 ( -.--% ) - $ 31-07-2026

Actieve functies van Carl Gordon

BedrijvenFunctieBegin
COMPASS THERAPEUTICS, INC. Voorzitter 01-01-2015
BLOSSOMHILL THERAPEUTICS, INC. Directeur/Bestuurslid 01-02-2021
SCRIBE THERAPEUTICS INC. Directeur/Bestuurslid 01-03-2021
Oprichter 01-01-1989
Directeur/Bestuurslid -
Directeur/Bestuurslid -
X4 Pharmaceuticals (Austria) GmbH
Directeur/Bestuurslid -
Directeur/Bestuurslid -
Directeur/Bestuurslid -
░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ -
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ -

Eerdere bekende functies van Carl Gordon

BedrijvenFunctieEinde
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
Ervaring van Carl Gordon in detail bekijken

Opleiding van Carl Gordon

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

62

Eerstegraads connecties

61

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit61

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Finance

Finance

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

X4 Pharmaceuticals (Austria) GmbH

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Carl Gordon